Dr. Robert S. Rahimi, MD

Dr. Rahimi practices at Baylor University Medical Center in Dallas, Texas, part of Baylor Scott & White Health.

Dr. Rahimi's NPI, 1093927188, was assigned on May 3, 2007. Dr. Rahimi graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2006. Dr. Rahimi holds Texas license N4017.

Dr. Rahimi's primary practice is Baylor University Medical Center, at 3500 Gaston Ave, Dallas, TX 75246 in Dallas County. The practice phone is (214) 820-8082.

Dr. Rahimi's primary practice is Baylor University Medical Center in Dallas, Texas, part of Baylor Scott & White Health. The medical group on file is HealthTexas Provider Network (HTPN). Dmand AI also links Dr. Rahimi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rahimi practices, 2 sites in all. Vendor and product names are available with a free account.

Hepatology is Dr. Rahimi's primary specialty in the NPI Registry, under taxonomy code 207RI0008X. Dr. Rahimi is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Rahimi's licenses on file in 2 states: Texas and Virginia.

Dmand AI lists cirrhosis of the liver, colonoscopy, electrolyte disorders, hepatitis c and upper GI endoscopy among the conditions Dr. Rahimi treats.

CMS data shows 419 Medicare services from Dr. Rahimi across 10 procedure codes in 2024, for 175 Medicare patients. Medicare paid $40,049 for them.

CMS counts 175 Medicare patients who saw Dr. Rahimi in 2024. The largest group is 65 to 74, with 104 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rahimi's median patient age at 63, with 47% women.

In 2024, Dr. Rahimi wrote 427 Medicare Part D claims for 104 patients. 91% of them were for generic drugs. CMS names the drug for 340 of them, across 13 drugs with 11 or more claims each, at $70,359 in total drug cost. In 2023, CMS named 488 claims across 14 drugs.

Dr. Rahimi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rahimi as offering telehealth. CMS counts 19 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Rahimi, more than 49% of the clinicians it reports for that procedure.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 83 papers to Dr. Rahimi, published from 2012 to 2025. 2020 was the busiest year, with 9. The most frequent topics are Liver Cirrhosis, Hepatic Encephalopathy and Liver Transplantation. Dr. Rahimi has published most often in Clin Gastroenterol Hepatol. Dr. Rahimi's most frequent co-authors are Elizabeth Clarice Verna, MD, Daniel R. Ganger, MD and Daniela P. Ladner, MD.

Dmand AI links Dr. Rahimi to 5 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Cholangitis, Cholangitis, Sclerosing and Hepatic Encephalopathy. Open Payments lists research payments to Dr. Rahimi that name 1 trial.

CMS Open Payments shows 265 general payments to Dr. Rahimi from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Mallinckrodt Hospital Products Inc. paid the most, $10,203. It also lists 19 research payments totaling $39,205 in 2019, naming 1 clinical trial.

Dr. Rahimi graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 2006. Dr. Rahimi is a member of American Association for the Study of Liver Diseases (AASLD), AGA and TMA.

Dr. Rahimi is in network with 21 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.